• Clarity Pharmaceuticals hit the enrollment target for the main cohort expansion group in its Phase I/IIa SECuRE prostate cancer trial.
• Prior results were presented on Aug. 5, 2026; additional cohort expansion updates are expected in coming months as data mature.
• Early findings showed favorable safety with encouraging anti-tumor activity, including meaningful disease control in evaluable patients.
• Recruitment continues for an additional cohort testing the therapy in combination with enzalutamide, broadening the program’s commercial positioning.
• Management indicated planning has started for a registrational Phase III theranostic trial based on preliminary SECuRE results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610080901PR_NEWS_USPR_____CN66697) on October 08, 2026, and is solely responsible for the information contained therein.